Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 223 clinical trials
featured
COVID-19 Treatment Trial: Investigational Medication as a Non-antiviral Immunomodulator

. - Arm A: CD24Fc / Best Available Treatment - Arm B: placebo / Best Available Treatment  CD24Fc will be administered as single dose of 480 mg via IV infusion on

  • 4013 views
  • 17 Jun, 2020
  • 4 locations
featured
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with

movement disorder
cognitive impairment
dementia
  • 78 views
  • 24 Jan, 2020
  • 1 location
featured
Alpha-Synuclein Kinetics

cleared from the body), we will use 3 proven approaches to determine this. 10 days of oral-labeling followed by 5 subsequent LPs 16 hours of IV infusion of the label, one lumbar

alpha-synuclein
  • 49 views
  • 24 Jan, 2020
  • 1 location
featured
Lilly H0P-MC-CPMP – BACK PAIN

participants will receive the study medication and one out of every three will be receive a placebo. The medication is given by an intravenous (IV) infusion every 2 weeks for a total of 4 infusions. Participants

  • 87 views
  • 23 Nov, 2020
  • 1 location
featured
Do You Suffer From Osteoarthritis Of The Knee?

Do You Suffer From Osteoarthritis Of The Knee?

  • 620 views
  • 08 Nov, 2020
  • 1 location
featured
Do You Experience Painful Diabetic Neuropathy?

We are currently seeking volunteers who are diagnosed with Diabetic Peripheral Neuropathic Pain and who experience pain daily.  This is a study of a new investigational medication that may help to relieve the pain of Diabetic Neuropathy.

peripheral neuropathic pain
diabetic peripheral neuropathic pain
  • 97 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

  • 82 views
  • 25 Mar, 2021
  • 1 location
featured
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

  • 167 views
  • 08 Nov, 2020
  • 1 location
  • 0 views
  • 18 Sep, 2021
  • 16 locations
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma

, patients will receive 375 mg/m2 of rituximab (US, Canada – Rituxan®; EU - Mabthera®), given as an IV infusion once weekly for 4 weeks. In Arm B, patients will receive Iodine I 131 Tositumomab

ct scan
rituximab
rituxan
tositumomab
measurable disease
  • 24 views
  • 07 Nov, 2020
  • 4 locations